Arcus Biosciences (RCUS) Interest Expenses (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Interest Expenses of $3.0 million for Q1 2026, up 50.0% year-over-year from $2.0 million in Q1 2025, and up 200.0% quarter-over-quarter from $1.0 million in Q4 2025.
Arcus Biosciences (RCUS) Interest Expenses (2017 - 2026) Analysis & Trends
Arcus Biosciences' Interest Expenses history runs 10 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 50.0% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $9.0 million (up 200.0% YoY), while the FY2025 annual figure was $412.0 million, up 30.38% from the prior year.
- Interest Expenses for Q1 2026 stood at $3.0 million, up from $1.0 million in the prior quarter.
- The five-year high for Interest Expenses was $9.8 million in Q3 2022, with the low at -$2.0 million in Q4 2023.
- The 5-year median for Interest Expenses is $3.0 million (2023), against an average of $3.0 million.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses slumped 128.57% in 2023, then soared 300.0% in 2025.
- Arcus Biosciences' Interest Expenses stood at $7.0 million in 2022, then slumped by 128.57% to -$2.0 million in 2023, then jumped by 50.0% to -$1.0 million in 2024, then surged by 200.0% to $1.0 million in 2025, then surged by 200.0% to $3.0 million in 2026.
- Business Quant data shows RCUS's Interest Expenses at $3.0 million in Q1 2026, $1.0 million in Q4 2025, and $4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.00 Mn |
| Jun 30, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 4.00 Mn |
| Sep 30, 2025 | 4.00 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Dec 31, 2024 | -1.00 Mn |
| Dec 31, 2024 | -1.00 Mn |
| Sep 30, 2024 | 1.00 Mn |
| Sep 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.00 Mn |